PredictorNCT07319689
Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients
An observational study of Predictor and Myasthenia Gravis, run by Tanta University at 1 site in Egypt.
Trial summary
This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Predictor, Myasthenia Gravis, Thoracoscopic Thymectomy
- What is being tested?
- Data collection
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2022to 18 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study was a combined prospective and retrospective, observational, and comparative study conducted in the neurology and cardiothoracic departments at Tanta and Zagazig University Hospitals between January 2022 and December 2025.
Who may be able to join
- Both sexes.
- Confirmed diagnosis of Myasthenia Gravis (MG).
- Underwent Thoracoscopic thymectomy.
- Availability of complete preoperative and postoperative records, including imaging and histopathology.
- Minimum follow-up of 9 months post-surgery.
Who cannot join
- Patients who underwent thymectomy for indications other than MG.
- Incomplete medical records or loss to follow-up before outcome assessment.
- Patients with concomitant neuromuscular disorders other than MG
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Multicenter Comparative Study Between Thymomatous and Non-Thymomatous Patients
This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.
Read the detailed description
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness resulting from antibodies that target acetylcholine receptors or associated proteins at the neuromuscular junction.
Thoracoscopic thymectomy becomes more prominent than traditional transsternal thymectomy due to fewer perioperative complications with shorter hospital stays and more favorable long-term outcomes.
Prognostic outcomes following thoracoscopic thymectomy can vary significantly between non-thymomatous and thymomatous MG, necessitating a thorough investigation of these differences.
- Being tested
- Data collection
- Medical subject headings
- Myasthenia Gravis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data collectionOther
Data were obtained from patient files, operative notes, and electronic medical records.
| Study group | Role | What they receive |
|---|---|---|
| Thymomatous Myasthenia Gravis group | Thymomatous myasthenia gravis (patients with histologically confirmed thymoma). Receives: Other: Data collection | |
| Non-thymomatous Myasthenia Gravis group | Non-thymomatous myasthenia gravis (patients with thymic hyperplasia or normal/ involuted thymus). Receives: Other: Data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients achieving complete stable remission
Proportion of patients achieving complete stable remission was recorded.
Measured: 12 months post-procedure
Secondary outcomes (1)
Proportion of patients achieving pharmacologic remission
Proportion of patients achieving pharmacologic remission was recorded.
Measured: 12 months post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
- Study start1 Jan 2022
- Primary completion18 Dec 2025
- Study completion18 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PredictorStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mostafa Mohamed Elawady, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07319689
- Sponsor's protocol ID
- 36264PR13103/10/25
- Status last verified
- Dec 2025
- First submitted
- 20 Dec 2025
- Last updated
- 6 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Multicenter Comparative Study Between Thymomatous and Non-Thymomatous Patients
- ClinicalTrials.gov ID
- NCT07319689
- Acronym / sponsor ID
- 36264PR13103/10/25
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 18 Dec 2025 (actual)
- Study completion
- 18 Dec 2025 (actual)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.
Detailed description
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness resulting from antibodies that target acetylcholine receptors or associated proteins at the neuromuscular junction.
Thoracoscopic thymectomy becomes more prominent than traditional transsternal thymectomy due to fewer perioperative complications with shorter hospital stays and more favorable long-term outcomes.
Prognostic outcomes following thoracoscopic thymectomy can vary significantly between non-thymomatous and thymomatous MG, necessitating a thorough investigation of these differences.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Thymomatous Myasthenia Gravis group | – | Other: Data collectionThymomatous myasthenia gravis (patients with histologically confirmed thymoma). |
| Non-thymomatous Myasthenia Gravis group | – | Other: Data collectionNon-thymomatous myasthenia gravis (patients with thymic hyperplasia or normal/ involuted thymus). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study was a combined prospective and retrospective, observational, and comparative study conducted in the neurology and cardiothoracic departments at Tanta and Zagazig University Hospitals between January 2022 and December 2025.
Key inclusion criteria (5 listed)
- Both sexes.
- Confirmed diagnosis of Myasthenia Gravis (MG).
- Underwent Thoracoscopic thymectomy.
- Availability of complete preoperative and postoperative records, including imaging and histopathology.
- Minimum follow-up of 9 months post-surgery.
Key exclusion criteria (3 listed)
- Patients who underwent thymectomy for indications other than MG.
- Incomplete medical records or loss to follow-up before outcome assessment.
- Patients with concomitant neuromuscular disorders other than MG
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Data collectionData were obtained from patient files, operative notes, and electronic medical records. | Other | Non-thymomatous Myasthenia Gravis group, Thymomatous Myasthenia Gravis group |
Primary outcome
Proportion of patients achieving complete stable remission
Time frame: 12 months post-procedure
Proportion of patients achieving complete stable remission was recorded.
1 secondary outcome
Proportion of patients achieving pharmacologic remission
Time frame: 12 months post-procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Predictor
Not yet recruitingObservational study
Beta-2-Trace Protein in Diabetic Nephropathy
Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus
RecruitingObservational study
Role of EEG in Differentiation Between Ischemic and Hemorrhagic Stroke
Acute Ischemic Stroke, Acute Haemorrhagic Stroke
RecruitingObservational study
Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension
Sleep Apnea, Obstructive Sleep Apnea
Recruiting
NIRS Monitoring in the NICU and AKI
Acute Kidney Injury (AKI), Postnatal AKI
RecruitingObservational study
Geographic Mismatch as A Predictor of Short-Term Major Adverse Cardiovascular Events Following Long Coronary Stent Implantation
Geographic Mismatch, Short-Term
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Predictor and Myasthenia Gravis, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients achieving complete stable remission (time frame: 12 months post-procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.